News
PathoQuest Reiterates its Strategic Growth Plans by Appointing Daniel Spasic to the Board
News ReleaseDaniel Spasic, a highly experienced lifescience business leader, has been appointed as a non-executive director to the board of PathoQuest. With over 25 years of hands-on experience in the growth and development of businesses within the industry, Mr...
The updated ICH Q5A(R2) draft guidance has been released
News ReleasePathoQuest, a leader in the development and provision of Next Generation Sequencing (NGS) testing services for the biopharmaceutical industry, is excited to announce that the updated ICH Q5A(R2) draft guidance for the “Viral Safety Evaluation of...
PathoQuest Announce the Opening of its New U.S. Facility
Press ReleaseThe Leading Experts in NGS Biosafety Testing and Characterization of Biopharmaceuticals Launch New Capabilities in the Critical U.S. MarketWayne, PA, and Paris, France – October 4, 2022 – PathoQuest, a leader in the development and provision of Next...
A Podcast from Transgene: NGS-Based Biosafety Strategy for Breakthrough Virus-Based Immunotherapies
Transgene is a French biotech developing virus-based immunotherapies. There manufacturing processes deal with breakthrough therapeutic vaccines highly awaited by patients.
It is critical to ensure compliance in a fast and safe way, they chose PathoQuest because NGS is the most suitable and rapid approach to assess the raw materials and biological products for viral contaminants.
PathoQuest Appoints Rainer Metzger, Ph.D. as Chairman of the Board of Directors
Rainer Metzger works as a business professional in the Life Science and Pharmaceutical Industry. He has led numerous partnerships for co-development, commercialization, M&A and licensing. Rainer has been in leading positions in precision medicine, initiating and managing partnerships and services for clinical trials, co-development, and commercialization with QIAGEN, ROCHE, DANAHER and MEDICOVER establishing and running business with pharmaceutical companies. Rainer is acting as a board member for a series of Biotech companies in Europe and the US. He holds a Diploma in natural sciences and genetics and a PhD in Biology and Pharmacology from the University of Heidelberg.
They talk about us: Staying abreast of regulations with NGS-based viral safety for faster, safer and more ethical lot release of vaccines.
In this European Pharmaceutical Review article, Sridhar Pennathur, Vice President, Analytical Development at Novavax, highlights the value of next generation sequencing in their vaccine production operations by answering key questions.
Pick another category:
Click here to learn more about PathoQuest’s Biologics Genomic Service for biopharmaceutical companies.
Connect
